SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized, double-blind study. J Bone Miner Res 20: 141151.
  • 2
    McAlister FA, Laupacis A, Wells GA, Sackett DL 1999 Users' guides to the medical literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282: 13711377.
  • 3
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42: 12461254.
  • 4
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 15861592.
  • 5
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231236.
  • 6
    Carmona RH 2004 Bone Health and Osteoporosis: A Report of the Surgeon General. United States Department of Health and Human Services. Available online at www.hhs.gov/surgeongeneral/library/bonehealth/content.html. Accessed November 4, 2004.
  • 7
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 10511056.
  • 8
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 19: 12501258.
  • 9
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE 2004 Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20: 20312041.
  • 10
    Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between change in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7: 255261.
  • 11
    Bauer DC, Santora A, Hochberg MC, Melton M, Ross P 2004 Alendronate reduces fracture risk in lowest bone turnover group. Bone 34 (Suppl 1): S92.
  • 12
    Hosking D, Emkey RD, Santora AC, Liberman UA 2004 Fracture risk remains reduced in patients with lowest bone turnover after 10 years of alendronate treatment. Abstract P2–519. Endocrine Society's 86th Annual Meeting Program and Abstracts, ENDO 2004, June 16–19, 2004, New Orleans, LA, USA.
  • 13
    Recker R, Ensrud K, Diem S, Cheng E, Bare S, Masarachia P, Roschger P, Fratzl P, Klaushofer K, Lombardi A, Kimmel D 2004 Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 19: S1S45.